1505A Adams Drive
About KariusKarius is a life sciences company focused on conquering infectious diseases through the innovative use of next-generation sequencing to analyze microbial cell-free DNA. The company’s genomics platform delivers unprecedented insight into the microbial landscape, providing clinicians with a comprehensive test capable of identifying more than a thousand pathogens directly from blood and helping industry accelerate drug development. For more information visit kariusdx.com and follow us on Twitter at @kariusdx.
CEO: Mickey Kertesz, PhD
CSO: Tim Blauwkamp, PhD
CTO: Sivan Bercovici, PhD
CFO: Brian Jung, MBA, MPH
Medical Director: David K. Hong, MD
Head of Global Innovation and Partnerships: Simona Zompi, MD, PhD
Board Member and Advisor: Rich Rava, PhD
Scientific Co-Founder & Chair of the Scientific Advisory Board: Steve Quake, PhD
20 articles with Karius
Leading authority on infectious disease, Dr. Bradley Perkins, to accelerate clinical evidence of the Karius Test™, a liquid biopsy for infectious disease
Karius Launches Multicenter Study to Evaluate the Diagnostic Value of the Karius Test for Pneumonia in Immunocompromised Patients
Karius, the world leader in liquid biopsy for infectious diseases, announced today active enrollment in a multicenter, prospective study that will evaluate the diagnostic value of the Karius ® Test for pneumonia in immunocompromised adult patients including those with hematological cancers. The Karius Test is a non-invasive bloo
“This transformative round will allow Karius to help more patients faster, fuel the next wave of clinical studies and accelerate technology innovation,” said Karius’ chief executive officer Mickey Kertesz.
Karius will present six studies at IDWeek™ 2019 highlighting the clinical utility of the Karius Test.
Karius, a life sciences company, announced today that the peer-reviewed journal Nature Microbiology published a study validating the Karius® Test for detecting pathogens and showing that the test identifies pathogens potentially faster than standard testing.
Companies are filling in the gaps and the entire area of so-called “liquid biopsies” is hot these days, with companies like Guardant Health, Karius, Freenome, Apostle and GRAIL Bio entering the market. With this backdrop, let’s look at some companies working in the same field as the now-defunct T...
Karius, a life sciences company transforming infectious disease diagnostics with genomics, is forming a partnership with Dasa, the largest medical diagnostic company in Latin America, effective October 19, 2018.
The quantitative next-generation sequencing blood test for infectious diseases makes an international impact
10/5/2018Guardant Health went on the Nasdaq yesterday under the symbol GH. Shares climbed almost 70 percent on the first day of trading, selling 12.5 million shares at $19 per share in the initial public offering (IPO).
Karius today announced the winners for its 2018 Clinical Investigator Awards for Applied Infectious Disease Genomics.
Ilan Danieli, chief executive officer and co-founder of Precipio, a company with a liquid biopsy technology, took time to talk to BioSpace about the company and the economics of liquid biopsies.
Some diagnostics testing for infectious diseases can be quite invasive and uncomfortable for a patient. Now though, a new form of test is available that can mitigate the need for those invasive tests.
Journal of Diagnostic Microbiology and Infectious Disease Publishes New Clinical Study Data on Karius Test
Study Confirms Liquid Biopsy for Infectious Diseases Accurately Detects Invasive Fungal Infections
Karius Announces Launch of Quantitative, Broad-Based Infectious Disease Diagnostic Test Using Microbial Cell-Free DNA Test Detects and Quantifies DNA from Bacteria, Viruses and Fungi in a Single Blood Sample
Karius announced today that the new version of its proprietary Karius Test can now quantify the abundance of pathogens detected.
A look at 6 up and coming blood-testing startups.
Karius Test Demonstrates Ability To Detect Pathogens From Cell-Free DNA Using Next-Generation Sequencing